beta-cell dysfunction

If insulin resistance is a stiff lock, beta-cell dysfunction is a tiring locksmith. The beta cells are the body's only source of insulin, and for a while they compensate for resistance by making extra. But like any overworked machine, they can falter — secreting too little, too slowly, or at the wrong moments — and that failure is what tips a struggling system into outright diabetes.

Beta-cell dysfunction means impaired insulin secretion: the cells lose the brisk, glucose-triggered release of insulin, especially the rapid ‘first-phase’ burst that normally follows a meal. In type 2 diabetes it develops alongside insulin resistance, with progressive loss of beta-cell mass and function over years driven by glucotoxicity (damage from chronic high glucose), lipotoxicity (damage from excess fatty acids), and the stress of constant oversecretion.

Crucially, type 2 diabetes does not appear until beta cells can no longer compensate, so dysfunction is the gatekeeper to overt disease. In type 1 diabetes the dysfunction is absolute and immune-mediated, whereas monogenic forms (MODY) stem from single-gene defects in the beta cell's glucose-sensing or insulin-secreting machinery. Some beta-cell decline can be slowed by relieving glucose and lipid overload, but much of the loss is difficult to reverse.